Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Queensland Health
Julphar
Medtronic
Accenture
Cantor Fitzgerald
Johnson and Johnson
Boehringer Ingelheim
Cipla

Generated: October 19, 2018

DrugPatentWatch Database Preview

Olaparib - Generic Drug Details

« Back to Dashboard

What are the generic sources for olaparib and what is the scope of olaparib freedom to operate?

Olaparib is the generic ingredient in one branded drug marketed by Astrazeneca Pharms and is included in two NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are three drug master file entries for olaparib. One supplier is listed for this compound.

Summary for olaparib
Pharmacology for olaparib

US Patents and Regulatory Information for olaparib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-001 Aug 17, 2017 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-001 Aug 17, 2017 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Astrazeneca Pharms LYNPARZA olaparib CAPSULE;ORAL 206162-001 Dec 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Astrazeneca Pharms LYNPARZA olaparib CAPSULE;ORAL 206162-001 Dec 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for olaparib

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0150012 00136 Estonia ➤ Sign Up PRODUCT NAME: OLAPARIIB;REG NO/DATE: EU/1/14/959 18.12.2014
3 50005-2015 Slovakia ➤ Sign Up PRODUCT NAME: OLAPARIB; REGISTRATION NO/DATE: EU/1/14/959 20141218
2015016 Lithuania ➤ Sign Up PRODUCT NAME: OLAPARIBUM; REGISTRATION NO/DATE: EU/1/14/959 20141216
15/016 Ireland ➤ Sign Up PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
680 Luxembourg ➤ Sign Up PRODUCT NAME: OLAPARIB AINSI QUE DES SELS ET DES SOLVATES DE CELUI-CI. FIRST REGISTRATION: 20141218
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Queensland Health
Julphar
Medtronic
Accenture
Cantor Fitzgerald
Johnson and Johnson
Boehringer Ingelheim
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.